Stockscreener 앱 받기
91.94
1.87%
-1.755
시간 외 거래:
91.94
0.005
+0.01%
전일 마감가:
$93.69
열려 있는:
$94.02
하루 거래량:
789.30K
Relative Volume:
1.27
시가총액:
$4.37B
수익:
$338.46M
순이익/손실:
$-310.96M
주가수익비율:
-14.08
EPS:
-6.53
순현금흐름:
$-132.82M
1주 성능:
+14.85%
1개월 성능:
-1.68%
6개월 성능:
+9.79%
1년 성능:
+7.55%
1일 변동 폭
$91.81
$94.89
1주일 범위
$80.98
$95.36
52주 변동 폭
$64.11
$105.00
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
AXSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
91.94 | 4.37B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
3,000 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Flower City Capital - MarketBeat
Zacks Research Issues Pessimistic Forecast for AXSM Earnings - MarketBeat
Axsome Asks FDA to Approve Questionable Alzheimer’s Agitation Drug - Being Patient
When Will Axsome Therapeutics, Inc. (NASDAQ:AXSM) Turn A Profit? - Simply Wall St
Axsome reports mixed results for Alzheimer's agitation drug - MSN
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $129.43 - MarketBeat
William Blair Has Positive Forecast for AXSM FY2024 Earnings - MarketBeat
William Blair Has Positive Estimate for AXSM FY2024 Earnings - MarketBeat
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last? - MSN
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Axsome’s 2024 Results Show Growth in Sunosi Sales and Progress for AXS-12 - Sleep Review
Pallas Capital Advisors LLC Purchases Shares of 26,435 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Truist raises Axsome Therapeutics target to $180, maintains Buy By Investing.com - Investing.com Canada
Objective long/short (AXSM) Report - Stock Traders Daily
Axsome Therapeutics (NASDAQ:AXSM) Shares Up 5.3% After Analyst Upgrade - MarketBeat
Axsome Therapeutics' (AXSM) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Axsome Therapeutics, Inc. Provides Preliminary Unaudited Total Product Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue - The Manila Times
Truist raises Axsome stock target to $180, maintains buy rating - Investing.com
Truist raises Axsome stock target to $180, maintains buy rating By Investing.com - Investing.com UK
JPMorgan Chase & Co. Raises Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
What is Zacks Research's Forecast for AXSM FY2024 Earnings? - MarketBeat
Excessive Daytime Sleepiness Clinical and Non-Clinical - openPR
Axsome Therapeutics (NASDAQ:AXSM) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook - Yahoo Finance
Axsome to seek approval of AXS-05 to treat agitation in... - Alzheimer's News Today
Axsome to lean on totality of data in Alzheimer’s agitation submission - BioCentury
Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome. - Barron's
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing - BioSpace
Axsome Therapeutics stock steady as Baird reiterates confidence in long-term prospects - Investing.com Canada
GLP-1 questions emerge for 2025 [Video] - AOL
Axsome shares boosted by strong Phase 3 outcomes and Buy rating reiteration - Investing.com Canada
These 13 Things Could Make You More Likely to Get Alzheimer's, According to Research - AOL
Short Interest in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Declines By 7.9% - MarketBeat
Leerink reiterates Outperform on Axsome stock despite FDA uncertainty for Auvelity - Investing.com Canada
Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $122.00 at Mizuho - MarketBeat
Axsome Therapeutics Remains A Buy Despite AXS-05’s Mixed Results (NASDAQ:AXSM) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results - Benzinga
Axsome’s Alzheimer’s drug shows promise in trials By Investing.com - Investing.com Nigeria
Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data - MedCity News
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation - Yahoo! Voices
Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains Bullish - MSN
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap DownHere's Why - MarketBeat
Smart Money Is Betting Big In AXSM Options - Benzinga
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data - Reuters.com
Axsome's Alzheimer's drug shows promise in trials - Investing.com India
Alzheimer's Agitation Drug Trial Data Mixed - Newsmax
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):